Sepsis-associated encephalopathy

Simona Cotena, Ornella Piazza, Simona Cotena, Ornella Piazza

Abstract

Sepsis-associated encephalopathy (SAE) is defined as a diffuse or multifocal cerebral dysfunction induced by the systemic response to the infection without clinical or laboratory evidence of direct brain infection. Its pathogenesis is multifactorial. SAE generally occurs early during severe sepsis and precedes multiple-organ failure. The most common clinical feature of SAE is the consciousness alteration which ranges from mildly reduced awareness to unresponsiveness and coma. Diagnosis of SAE is primarily clinical and depends on the exclusion of other possible causes of brain deterioration. Electroencephalography (EEG) is almost sensitive, but it is not specific for SAE. Computed Tomography (CT) head scan generally is negative in case of SAE, while Magnetic Resonance Imaging (MRI) can show brain abnormalities in case of SAE, but they are not specific for this condition. Somatosensitive Evoked Potentials (SEPs) are sensitive markers of developing cerebral dysfunction in sepsis. Cerebrospinal fluid (CBF) analysis is generally normal, a part an inconstant elevation of proteins concentration. S100B and NSE have been proposed like biomarkers for diagnosis of SAE, but the existing data are controversial. SAE is reversible even if survivors of severe sepsis have often long lasting or irreversible cognitive and behavioral sequel; however the presence of SAE can have a negative influence on survival. A specific therapy of SAE does not exist and the outcome depends on a prompt and appropriate treatment of sepsis as whole.

Keywords: S100B; Sepsis-associated encephalopathy; blood brain barrier; brain edema.

References

    1. Wilson JX, Young GB. Sepsis-associated encephalopathy: evolving concepts. Can. J. Neurol. Sci. 2003;30:98–105.
    1. ACCP/SSCM Medicine Consensus Committee Definition of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit care Med. 1992;20:864–874.
    1. Consales G, De Gaudio AR. Sepsis associated encephalopathy. Minerva Anestesiol. 2005 Jan-Fab;(1–2):71. 39–52.
    1. Sharshar T, Hopkinson NS, Orlikowski D, Annane D. Science review: The brain in sepsis-culprit and victim. Crit Care. 2005;9:37–44.
    1. Ikeda-Matsuo Y, Ikegaya Y, Matsuki N, Uematsu S, Akira S, Sasaki Y. Microglia-specific expression of microsomal prostaglandin E2 synthase-1 contributes to lipopolysaccharide-induced prostaglandin E2 production. J Neurochem. 2005;94:1546–1558.
    1. Fierl MA, Stahel PF, Rittirsch D, et al. Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis. Crit Care. 2009;13:R12.
    1. Esen F, Erdem T, Aktan D, et al. Effect of magnesium sulfate administration on blood-brain barrier in a rat model of intraperitoneal sepsis: a randomized controlled experimental study. Crit Care. 2005;9:R18–23.
    1. Piazza O, Cotena S, De Robertis E, Caranci F, Tufano R. Sepsis Associated Encephalopathy Studied by MRI and Cerebral Spinal Fluid S100B Measurement. Neurochem Res. 2009;34:1289–1292.
    1. Thees C, Kaiser M, Scholz M, et al. Cerebral haemodynamics and CO2 reactivity during sepsis syndrome. Crit Care. 2007;11:R123.
    1. Fong TG, Bogardus ST, Jr, Daftary A, et al. Cerebral perfusion changes in order delirious patients using 99mTc HMPAO SPECT. J Gerontol A Biol Sci Med Sci. 2006;61:1294–1299.
    1. Szatmàri S, Végh T, Csomòs A, et al. Impaired cerebrovascular reactivity in sepsis-associated encephalopathy studied by acetazolamide test. Crit Care. 2010;14:R50.
    1. Berg RMG, Taudorf S, Bailey DM, et al. Cerebral net exchange of large neutral amino acids after lipopolysaccharide infusion in healthy humans. Crit Care. 2010;14:R16.
    1. Zampieri FG, Park M, Machado FS, Azevedo LCP. Sepis-associated encephalopathy: not just delirium. Clinics. 2011;66(10):1823–1831.
    1. Ebersoldt M, Sharshar T, Annane D. Sepsis-associated delirium. Intensive Care Med. 2007;33:941–950.
    1. Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J. Posterior reversible encephalopathy syndrome in infection, sepsis and shock. AJNR Am J Neuroadiol. 2006;27:2179–90.
    1. Fugate JE, Claassen DO, Cloft HJ, Kallmes D, Kozak OS, Rabinstein AA. Posterior Reversible Encephalopathy Syndrome: Associated Clinical and Radiologic Findings. Mayo Clin Proc. 2010;85(5):427–432.
    1. Sharshar T, Carlier R, Bernard F, et al. Brain lesions in septic shock: a magnetic resonance imaging study. Intensive Care med. 2007;33:798–806.
    1. Zauner C, Gendo A, Kramer L, et al. Impaired subcortical and cortical sensory evoked potential pathways in septic patients. Crit care med. 2002 May;30(5):1136–9.
    1. Ohnesorge H, Bischoff P, Scholz J, Yekebas E, Schute am Esch J. Somatosensory evoked potentials as a predictor of systemic inflammatory response syndrome in pigs? Intensive Care Med. 2003 May;29(5):801–7.
    1. Nguyen DN, Spapen H, Su F, et al. Elevated serum levels of S-100β protein and neuron-specific enolase are associated with brain injury in patients with severe sepsis and septic shock. Crit Care Med. 2006;34(6):1–8.
    1. Piazza O, Russo E, Cotena S, Esposito G, Tufano R. Elevated S100B levels do not correlate with severity of encephalopathy during sepsis. Br J Anaesth. 2007;99:518–21.
    1. Larsson A, Lipcsey M, Sjolin J, Hansson LO, Eriksson MB. Slight increase of serum S100-B during porcine endotoxiemic shock may indicate blood-brain barrier damage. Anesth Analg. 2005;101:1465–9.
    1. Annane D. Sepsis-associated delirium: the pro and con of C5a blockade. Crit Care. 2009;13:135.
    1. Wang G, Wang W, Zhao J, Ni Y, Zhou X, Zhang W. Ghrelin prevents neuronal apoptosis and cognitive impairments in sepsis-associated encephalopathy. Neuroreport. 2011;22(18):959–64.
    1. Spapen H, Nguyen DN, Troubleyn J, Huyghens L, Schiettecatte J. Dotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock. Crit Care. 2010;14:R54.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj